Provectus Pharmaceuticals Inc. To Receive Patent For Novel Acne Product

KNOXVILLE, Tenn., Feb. 21 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. announced today it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application covering novel acne medications, including the Company's invisible, solid acne treatment, Pure-Stick(TM), which is an over- the-counter (OTC) product. This Allowance, which is the first for Provectus OTC products, is an important step in the Company's program to broaden and further extend its existing intellectual property portfolio.

The pending patent covers certain formulations and medical uses of topical cosmetic and medicinal compositions for treatment of facial acne. Acne is caused by skin conditions that make bacteria normally present on the skin proliferate and cause inflammation. A key trigger for this unchecked growth is excess oil on the skin. Provectus' unique formulations address a root cause of acne using a novel approach that combines agents to modify the skin with a powerful antibacterial agent to inhibit bacterial growth that can lead to acne.

Provectus CEO Craig Dees, Ph.D commented: "We believe that the uniqueness of our acne product could make it a strong contender in a multibillion dollar market. We continue to validate our strength in practical innovation with unique products such as this. Provectus is now expected to have 17 issued U.S. patents and remains confident in its 23 U.S. patent applications."

In addition to Pure-Stick, Provectus OTC products address important areas of skin care, and include Pure-ific(TM), a long lasting anti-infectious agent spray for hands or surfaces. The Company is seeking to spin-out, license or sell its OTC assets in key markets worldwide, noted Dees.

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals, Inc. is a pioneering pharmaceutical company actively engaged in the design and development of pharmaceutical technologies for the treatment of metastatic melanoma, breast cancer and liver cancer. Provectus is nearing completion of its 20-subject Phase 1 study of the safety and efficacy of PV-10, an injectable formulation of Rose Bengal also known as Provecta(TM), for the ablation of metastatic melanoma, an aggressive and often fatal form of skin cancer. Provectus expects to commence a pivotal Phase 2/3 study of the efficacy of PV-10 in the treatment of metastatic melanoma shortly thereafter. Provectus is also making progress towards completion of its extended Phase 1 recurrent breast cancer study. In addition, Provectus is preparing to begin Phase 2 clinical studies for the Company's topical agent Xantryl for psoriasis.

The Company's offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865-769-4011.

For more information, contact the Company at info@pvct.com or visit the corporate Web site: http://www.pvct.com.

This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward- looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward- looking statements.

Provectus Pharmaceuticals, Inc.

CONTACT: Peter Culpepper of Provectus Pharmaceuticals, Inc.,+1-865-769-4011, culpepper@pvct.com; or Investors, Matt Clawson of Allen &Caron Inc., +1-949-474-4300, matt@allencaron.com, for ProvectusPharmaceuticals, Inc.

Back to news